Ibrutinib Therapy and Mycobacterium chelonae Skin and Soft Tissue Infection
Keyword(s):
B Cell
◽
Abstract Ibrutinib is an irreversible inhibitor of Bruton’s tyrosine kinase approved for the treatment of B-cell malignancies. There is growing concern about the risk of opportunistic infections following ibrutinib therapy. Herein, we describe the first case of Mycobacterium chelonae skin and soft tissue infection in a patient receiving ibrutinib and recount the challenges in treating this infection.
2017 ◽
Vol 37
(4)
◽
pp. 346-348
◽
Keyword(s):
1995 ◽
Vol 17
(5)
◽
pp. 39-40
◽
Keyword(s):
Keyword(s):
2010 ◽
Vol 4
(08)
◽
pp. 521-525
◽
Keyword(s):
2020 ◽
Vol 155
(7)
◽
pp. 322-323
Keyword(s):
2009 ◽
Vol 22
(2)
◽
pp. 99-101
◽
Keyword(s):